-
公开(公告)号:EP2434891A4
公开(公告)日:2012-11-14
申请号:EP10781238
申请日:2010-05-27
申请人: PTC THERAPEUTICS INC
发明人: ALMSTEAD NEIL , ARASU TAMIL , CHOI SOONGYU , CAO LIANGXIAN , CAMPBELL JEFF , CORSON DON , DAVIS THOMAS W , GRACI JASON D , GU ZHENGXIAN , HWANG PETER SEONGWOO , LENNOX WILLIAM , MIAO HARRY H , MILLER LANGDON , MOON YOUNG-CHOON , QI HONGYAN , TROTTA CHRISTOPHER , WEETALL MARLA L
IPC分类号: A01N43/42 , A61K31/44 , C07D471/04
CPC分类号: C07D471/04 , A61K31/437 , A61K31/44 , A61K31/4745 , A61K45/06
摘要: Compounds, such as compounds of Formula (I), that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.
摘要翻译: 描述了选择性抑制人血管内皮生长因子(VEGF)的病理生成的化合物,例如式(I)的化合物和包含这些化合物的组合物。 描述了抑制病毒复制或产生病毒RNA或DNA或病毒蛋白的化合物和包含这些化合物的组合物。 还描述了使用这些化合物减少VEGF的方法和用于治疗涉及施用这些化合物的癌症和非肿瘤性病症的方法。 进一步描述的是使用这样的化合物和方法来治疗涉及施用这些化合物的病毒感染来抑制病毒复制或病毒RNA或DNA或病毒蛋白的产生的方法。 化合物可以作为单一药物治疗或与一种或多种另外的治疗组合施用于需要这种治疗的人。
-
公开(公告)号:EP2922828A4
公开(公告)日:2016-07-27
申请号:EP13857326
申请日:2013-11-21
申请人: PTC THERAPEUTICS INC
发明人: LEE CHANG-SUN , BAIAZITOV RAMIL , CAO LIANGXIAN , DAVIS THOMAS W , DU WU , LIU RONGGANG , MOON YOUNG-CHOON , PAGET STEVEN D , REN HONGYU , SYDORENKO NADIYA , WILDE RICHARD GERALD
IPC分类号: C07D403/04 , A61K31/506 , A61P35/00 , C07D405/14 , C07D471/04
CPC分类号: C07D403/12 , A61K31/506 , A61K45/06 , A61N5/10 , C07D403/04 , C07D471/04 , C07D487/04
摘要: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
-